High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration
1997

High-dose chemotherapy with carboplatin, etoposide, and melphalan for high-risk cancer

Sample size: 40 publication Evidence: moderate

Author Information

Author(s): P Benedetti Panicil, L Pierelli, G Scambia, ML Foddai, MG Salerno, G Menichella, M Vittori, F Maneschi, U Caracussi, R Serafini, G Leone, S Mancuso

Primary Institution: Catholic University, Rome, Italy

Hypothesis

Does high-dose carboplatin, etoposide, and melphalan with peripheral blood progenitor cell support reduce toxicity and improve recovery in high-risk cancer patients?

Conclusion

The study found that high-dose chemotherapy with carboplatin, etoposide, and melphalan resulted in low non-haematological toxicity and fast haematopoietic recovery.

Supporting Evidence

  • 32% of patients experienced a reversible grade III/IV increase in liver enzymes.
  • Haematopoietic recovery was very fast in all patients.
  • Patients treated with growth factors had significantly reduced hospital stays.

Takeaway

Doctors gave strong medicine to cancer patients to help them get better, and it worked well without making them too sick.

Methodology

Patients received high-dose chemotherapy followed by peripheral blood progenitor cell transplantation and were monitored for toxicity and recovery.

Limitations

The study was limited to a small sample size and specific cancer types.

Participant Demographics

Median age was 48 years, with patients having breast or ovarian cancer.

Statistical Information

P-Value

0.0001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication